BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Discgenics Announces the Appointment of Robert M. Wynalek as Chief Operating and Commercialization Officer


6/26/2012 10:26:33 AM

SALT LAKE CITY, June 26, 2012 /PRNewswire/ -- Discgenics, Inc. (Discgenics), a spinal therapeutics company that is developing a proprietary disc stem cell technology to treat degenerative disc disease, announces the appointment of Robert M. Wynalek as its Chief Operating and Commercialization Officer. Discgenics' CEO Flagg Flanagan said, "we are truly excited to have Bob join us in an executive capacity in addition to his role as a Discgenics board director and investor. Bob brings to Discgenics extensive leadership expertise in Biologics, Spinal Devices and Orthopedics having served most recently as President, Domestic at orthobiologics leader Osteotech, Inc. prior to its acquisition by Medtronic, Inc. during late 2010. This combined with his experience at Medtronic, Sofamor Danek Group, and Smith & Nephew Orthopedics, will bring tremendous benefits to Discgenics as we continue to develop and commercialize our science and technology for the treatment of degenerative disc disease."

About Discgenics, Inc.

Discgenics is a privately funded Spinal therapeutics company that is utilizing tissue engineering and adult human disc stem cell technology to develop a treatment for patients debilitated by degenerative disc disease. News and other information are available at: http://www.discgenics.com.

Media Contact: Flagg Flanagan
Chief Executive Officer
801-410-0703
flagg@discgenics.com

SOURCE Discgenics, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES